This multicenter, prospective, randomized, double-blind, placebo-controlled phase 2 study is evaluating the efficacy of letrozole-palbociclib combination against letrozole-placebo combination in women with ER+ advanced or relapsed endometrial cancer.~Stratification~Patients are stratified according to:~Number of prior lines of therapy (primary advanced disease vs. 1st relapse vs. ≥2 relapses)~Measurable vs. evaluable disease~Prior use of MPA/Megace~Randomization 1:1 randomization The patients with prior MPA/Megace treatment will be capped to a maximum of 50%.~Study arms~Patients are randomized to one of the two treatment arms:~Arm A: (comparator) letrozole-placebo combination therapy until progression.~Arm B: (experimental arm): Letrozole- palbociclib combination therapy until progression
This randomized double-blind, placebo-controlled phase 2 trial is evaluating superiority of Letrozole-palbociclib combination versus letrozole-placebo combination in ER positive endometrioid adenocarcinoma of endometrium